FDA approves treatment for the ‘world’s deadliest infectious disease’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/stockdevil)
(Image: Getty/stockdevil)

Related tags: Tb, Antibiotics, Infectious disease, Infectious diseases, FDA approval, Orphan drug

FDA approves the third anti-TB drug in more than 40 years after the compound showed significantly higher success rates in patients with multi drug-resistant and extensively drug-resistant TB.

The US Food and Drug Administration (FDA) approved TB Alliance’s pretomanid, a therapy for patients with extensively drug-resistant tuberculosis (TB) or multidrug-resistant TB.

Pretomanid is a compound developed by the non-profit organization TB Alliance and approved under the Limited Population Pathway for Antibacterial and Antifunal Drugs (LPAD) as part of a three-drug, six-month, all-oral regimen.

With this approval, pretomanid will be the third new anti-TB drug approved by the FDA in more than 40 years. It is the first treatment of its kind to be developed and registered by a not-for-profit organization.

The LPAD pathway was established by the FDA to enable further development of antibacterial and antifungal drugs to treat serious life-threatening infections that affect a limited population of patients.

The FDA also granted the drug priority review, qualified infectious disease product, and orphan drug status.

Mel Spigelman, president and CEO of TB Alliance stated, “FDA approval of this treatment represents a victory for the people suffering from these highly drug-resistant forms of the world’s deadliest infectious disease.” 

According to TB Alliance, the drug is a nitroimidazole, a class of novel antibacterial agents. Pretomanid acts in vitro against all tested drug-resistant clinical isolates and is an active bactericidal and sterilizing agent.

Pretomanid is part of a three-drug regimen that includes the use of bedaquiline and linezolid. The three drugs together can be referred to as the BPaL regimen. This three-drug regimen was studied in a Nix-TB trial across three sites in South Africa in patients with extensively drug-resistant TB, or multi-drug resistant TB.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...


Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers